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Macular disease (MD): 
• is a chronic, degenerative, largely incurable but 
sometimes treatable eye condition resulting in loss of 
central vision needed for e.g. driving, reading, face 
recognition 
• mainly affects over 55s and is the cause of > 90% of 
new registrations as blind in over 65s in UK and US1 
 
The MacDQoL2 
• is an individualised measure of the impact of MD on 
quality of life (QoL) 
• has 26 domains, each with an impact score and 
importance rating, multiplied to give a weighted impact 
score. A single average weighted impact score (AWI) 
averages weighted impact across domains applicable 
to the individual respondent 
• has 2 QoL overview items (1 generic, 1 MD-specific) 
• has face validity and preliminary evidence of internal 
consistency reliability and construct validity2 
 
Time trade-off (TTO) utility values: 
•  have been obtained for MD patients in other studies3 
• factors other than condition severity may influence   
utility values4 
• Completion rates:  MacDQoL questionnaire = 99%,         
health TTO item = 75%, vision TTO item = 71%. 
• Of those completing TTO items, percentages giving a utility 
value of 1 (U = 1, usually interpreted as indicating optimal 
vision) were: vision TTO = 38%, health TTO = 42% 
• U = 1 distributed equally between blind, partially sighted 
and not registered groups 
 
Methods 
• Lower TTO completion rates suggest reduced face 
validity and less acceptability of TTO questions. 
• TTO questions less sensitive to subgroup differences 
than MacDQoL (AWI) and MD-specific overview item. 
• Frequency and distribution of U = 1 and comments 
about TTO questions indicate that people may not be 
willing to co-operate with TTO utilities methodology 
and, when they are, their responses do not provide a 
measure of QoL. 
Conclusions 
Participants: 
• 171 recruited from the MD Society (UK) self-help 
groups (mean age 79 yrs, 77% women; registered 
blind n = 51, registered partially sighted n = 60,         
not registered n = 60) 
• if able to read, randomised to complete MacDQoL, TTO 
questions and SF-36 item by telephone interview or self-
completion 
• if unable to read had short telephone interview, completing 
MacDQoL overview items, TTO questions and SF-36 item 
• Vision-specific and health-specific TTO utility values were 
compared with: MacDQoL AWI, generic overview,  MD-
specific overview and SF-36 items 
• Spearman’s correlations (Table 1) indicated: 
⇒ TTO questions were not correlated with registration status, 
health status or MacDQoL variables 
⇒ MacDQoL AWI and MD-specific overview item were       
associated with registration status 
• Comments about TTO questions (Figure 1) recorded during 
phone interviewing indicated:  
⇒ questions difficult to answer 
⇒ people considered things other than their own QoL when 
answering the questions  
 
How many more 
years do you expect How do I know….?   
I could be dead by 
tonight! 
Figure 1. Reactions to TTO questions 
What is the maximum number of 
hears, if any, would you be willing 
to give up if you could have this 
treatment and have perfect vision 
for your remaining years? 
At 50 or 60 it would 
be different. At my 
time of life it’s not 
worth considering. 
Better to be around 
for the family even 
though incapacitated. 
Only god 
knows the 
answer to this. 
I’m blessed with a wonderful 
partner. As long as we’re 
together | would not give up any 
time for perfect vision. If I was on 
my own I might think differently 
Nonsense and hypothetical 
question. I’m amazed at an 
academic institution coming up 
with such a ridiculous question! 
 General health Health TTO Vision TTO MD-specific 
QoL 
Generic 
QoL 
Registra-
tion 
status 
MacDQoL 
AWI 
 0.089 0.065 0.098 0.639* 0.298* 0.444* 
Registra-
tion status 
-0.18 0.099 0.033 0.426* 0.004  
Generic 
QoL 
0.561* 0.15 0.1 0.069   
MD-
specific 
QoL 
-0.105 0.020 0.117    
Vision 
TTO 
0.054 0.731*     
Health 
TTO 
0.172      
Table 1. Correlations between outcome measures 
* significant at p < 0.01 
